XENE Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 23rd Annual Needham (Virtual) Healthcare Conference taking place April 8-11, 2024.

Company Fireside Chat Presentation Details:

Date:Thursday, April 11, 2024
  
Time:3:00 PM Eastern Time
  
Webcast:
  
Presenters:Ian Mortimer, President and Chief Executive Officer
 Sherry Aulin, Chief Financial Officer
  

A live webcast of the company presentation will be available on the “” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. For more information, please visit .

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:

For Investors:

Chad Fugere

Vice President, Investor Relations

(857) 675-7275

For Media:

Jodi Regts

Xenon Corporate Affairs

(604) 484-3353



EN
04/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xenon Pharmaceuticals Inc

Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong

ResearchPool Subscriptions

Get the most out of your insights

Get in touch